Cita APA

DEANDREIS, D., DURANTE, C., Luster, M., Netea-Maier, R., Capdevila Castillon, J., & Leboulleux, S. (2023). Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: A multidisciplinary perspective for daily practice.

Citación estilo Chicago

DEANDREIS, Desiree', COSIMO DURANTE, Markus Luster, Romana Netea-Maier, Jaume Capdevila Castillon, y Sophie Leboulleux. Use of Lenvatinib in the Treatment of Radioiodine-refractory Differentiated Thyroid Cancer: A Multidisciplinary Perspective for Daily Practice. 2023.

Cita MLA

DEANDREIS, Desiree', et al. Use of Lenvatinib in the Treatment of Radioiodine-refractory Differentiated Thyroid Cancer: A Multidisciplinary Perspective for Daily Practice. 2023.